Annovis Bio, Inc. is a clinical-stage pharmaceutical platform company targeting neurodegeneration such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The company’s pipeline includes Buntanetap, ANVS405 and ANVS301. Its lead product candidate Buntanetap is an orally administered drug being developed for chronic indications such as AD and PD. Buntanetap is a synthetically produced, small molecule, orally administered, brain-penetrating compound. In addition, it was found that Buntanetap protects nerve cells from dying in the brains of mice with traumatic brain injury and protects nerve cells from dying in the eye of glaucoma rats. ANVS405 is an intravenous drug being developed for acute indications and aims to protect the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same drug as Buntanetap, which is administered for acute head and brain trauma. ANVS301 is an orally administered drug being developed to improve cognitive abilities in later stages of AD and dementia.
Learn more about the company
2023-10-31 19:35:05
#Annovis #Bio #Prices #Million #Public #Offering #stocks #fall
